MGNX
MacroGenics, Inc. [MGNX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MGNX Stock Summary
Top 10 Correlated ETFs
MGNX
Top 10 Correlated Stocks
MGNX
In the News
MGNX Financial details
MGNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.29 | 1.86 | 1.26 | 2.47 | 0 | |
| Net income per share | -3.16 | -2.25 | -3.18 | -1.95 | 0 | |
| Operating cash flow per share | -2.79 | -2.13 | -2.4 | -1.42 | 0 | |
| Free cash flow per share | -2.88 | -2.25 | -2.5 | -1.47 | 0 | |
| Cash per share | 4.49 | 5.2 | 4.06 | 2.51 | 0 | |
| Book value per share | 4.8 | 5.64 | 4 | 2.31 | 0 | |
| Tangible book value per share | 4.8 | 5.64 | 4 | 2.31 | 0 | |
| Share holders equity per share | 4.8 | 5.64 | 4 | 2.31 | 0 | |
| Interest debt per share | 0.64 | 0.56 | 0.42 | 0.57 | 0 | |
| Market cap | 523.14M | 1.2B | 962.11M | 412.22M | 595.76B | |
| Enterprise value | 427.24M | 1.05B | 864.11M | 338.16M | 595.69B | |
| P/E ratio | -3.45 | -10.18 | -5.04 | -3.43 | -65.77K | |
| Price to sales ratio | 8.43 | 12.26 | 12.72 | 2.71 | 10.14K | |
| POCF ratio | -3.9 | -10.71 | -6.69 | -4.74 | -7.62K | |
| PFCF ratio | -3.78 | -10.18 | -6.41 | -4.55 | -7.45K | |
| P/B Ratio | 2.27 | 4.05 | 4.02 | 2.9 | 3.9K | |
| PTB ratio | 2.27 | 4.05 | 4.02 | 2.9 | 3.9K | |
| EV to sales | 6.89 | 10.71 | 11.42 | 2.23 | 10.14K | |
| Enterprise value over EBITDA | -2.57 | -7.99 | -4.26 | -2.79 | -3.54K | |
| EV to operating cash flow | -3.18 | -9.36 | -6.01 | -3.89 | -7.62K | |
| EV to free cash flow | -3.08 | -8.89 | -5.76 | -3.73 | -7.45K | |
| Earnings yield | -0.29 | -0.1 | -0.2 | -0.29 | 0 | |
| Free cash flow yield | -0.26 | -0.1 | -0.16 | -0.22 | 0 | |
| Debt to equity | 0.13 | 0.1 | 0.11 | 0.25 | 0.22 | |
| Debt to assets | 0.1 | 0.08 | 0.08 | 0.12 | 0.11 | |
| Net debt to EBITDA | 0.58 | 1.16 | 0.48 | 0.61 | 0.4 | |
| Current ratio | 5.31 | 6.17 | 3.75 | 4.57 | 4.48 | |
| Interest coverage | 0 | 0 | 0 | -461.67 | 117.65 | |
| Income quality | 0.88 | 0.86 | 0.71 | 0.73 | 8.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.74 | 0.44 | 0 | 0 | 0 | |
| Research and developement to revenue | 3.15 | 1.98 | 2.84 | 1.36 | 2.84 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.05 | 0.04 | 0.04 | 0.02 | |
| Capex to revenue | -0.07 | -0.06 | -0.08 | -0.02 | -0.03 | |
| Capex to depreciation | -0.4 | -0.49 | -0.55 | -0.31 | -0.38 | |
| Stock based compensation to revenue | 0.32 | 0.21 | 0.31 | 0.13 | 0.31 | |
| Graham number | 18.46 | 16.89 | 16.92 | 10.08 | 0 | |
| ROIC | -0.61 | -0.34 | -0.66 | -0.57 | -0.76 | |
| Return on tangible assets | -0.49 | -0.31 | -0.57 | -0.43 | -0.03 | |
| Graham Net | 2.98 | 3.95 | 2.64 | 0.96 | 0 | |
| Working capital | 194.62M | 261.92M | 204.98M | 173.57M | 195.23M | |
| Tangible asset value | 230.63M | 295.88M | 239.62M | 142.01M | 152.61M | |
| Net current asset value | 157.91M | 229.74M | 183.93M | 83.73M | 105.53M | |
| Invested capital | 0.13 | 0.1 | 0.11 | 0.25 | 0.22 | |
| Average receivables | 21.16M | 17.91M | 16.73M | 33.3M | 33.29M | |
| Average payables | 4.16M | 6.17M | 11.77M | 10.2M | 5.67M | |
| Average inventory | 0.5 | 1 | 2.19M | 2.92M | 1.34M | |
| Days sales outstanding | 75 | 86.17 | 50.12 | 135.06 | 64.41 | |
| Days payables outstanding | 8.05 | 15.17 | 2.13K | 242.16 | 3.8K | |
| Days of inventory on hand | 0 | 0 | 604.16 | 71.72 | 719.98 | |
| Receivables turnover | 4.87 | 4.24 | 7.28 | 2.7 | 5.67 | |
| Payables turnover | 45.34 | 24.06 | 0.17 | 1.51 | 0.1 | |
| Inventory turnover | 195.31M | 193.2M | 0.6 | 5.09 | 0.51 | |
| ROE | -0.66 | -0.4 | -0.8 | -0.85 | -0.06 | |
| Capex per share | -0.09 | -0.11 | -0.1 | -0.06 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.16 | 0.39 | 0.21 | 0.17 | 0 | |
| Net income per share | 0.21 | -0.62 | 0.92 | 0.28 | 0 | |
| Operating cash flow per share | 0.48 | -0.21 | -0.03 | -0.57 | 0 | |
| Free cash flow per share | 0.47 | -0.21 | -0.04 | -0.57 | 0 | |
| Cash per share | 2.51 | 3.91 | 3.86 | 4.12 | 0 | |
| Book value per share | 2.31 | 1.77 | 2.76 | 3.12 | 0 | |
| Tangible book value per share | 2.31 | 1.77 | 2.76 | 3.12 | 0 | |
| Share holders equity per share | 2.31 | 1.77 | 2.76 | 3.12 | 0 | |
| Interest debt per share | 0.57 | 0.57 | 0.56 | 0.55 | 0 | |
| Market cap | 412.22M | 443.18M | 333.1M | 290.06M | 595.76B | |
| Enterprise value | 338.16M | 253.46M | 258.66M | 234.27M | 595.69B | |
| P/E ratio | 8.05 | -2.9 | 1.45 | 4.13 | -3.25K | |
| Price to sales ratio | 5.79 | 18.3 | 25.36 | 27.9 | 54.15K | |
| POCF ratio | 14.06 | -34.53 | -159.45 | -8.23 | -21.25K | |
| PFCF ratio | 14.25 | -33.59 | -140.25 | -8.11 | -20.79K | |
| P/B Ratio | 2.9 | 4.06 | 1.94 | 1.5 | 3.9K | |
| PTB ratio | 2.9 | 4.06 | 1.94 | 1.5 | 3.9K | |
| EV to sales | 4.75 | 10.47 | 19.69 | 22.53 | 54.14K | |
| Enterprise value over EBITDA | 22.23 | -6.79 | 4.44 | -6.6 | -3.93K | |
| EV to operating cash flow | 11.53 | -19.75 | -123.82 | -6.65 | -21.25K | |
| EV to free cash flow | 11.69 | -19.21 | -108.91 | -6.55 | -20.79K | |
| Earnings yield | 0.03 | -0.09 | 0.17 | 0.06 | 0 | |
| Free cash flow yield | 0.07 | -0.03 | -0.01 | -0.12 | 0 | |
| Debt to equity | 0.25 | 0.32 | 0.2 | 0.18 | 0.22 | |
| Debt to assets | 0.12 | 0.1 | 0.11 | 0.1 | 0.11 | |
| Net debt to EBITDA | -4.87 | 5.08 | -1.28 | 1.57 | 0.44 | |
| Current ratio | 4.57 | 6.33 | 3.52 | 5.68 | 4.48 | |
| Interest coverage | 0 | -58.58 | -58.09 | 0 | 17.26 | |
| Income quality | 2.29 | 0.34 | -0.04 | -2.01 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.64 | 1.89 | 3.29 | 2.9 | 4.3 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.01 | 0.03 | 0.14 | 0.01 | 0.02 | |
| Capex to revenue | -0.01 | -0.01 | -0.02 | -0.05 | -0.06 | |
| Capex to depreciation | -0.12 | -0.12 | -0.1 | -0.26 | 0.2 | |
| Stock based compensation to revenue | 0.07 | 0.2 | 0.33 | 0.46 | 0.4 | |
| Graham number | 3.29 | 4.96 | 7.56 | 4.45 | 0.01 | |
| ROIC | 0.06 | -0.22 | -0.19 | -0.15 | -0.24 | |
| Return on tangible assets | 0.05 | -0.11 | 0.19 | 0.05 | -0.15 | |
| Graham Net | 0.96 | 0.57 | 1.8 | 2.09 | 0 | |
| Working capital | 173.57M | 243.33M | 172.14M | 240.03M | 195.23M | |
| Tangible asset value | 142.01M | 109.27M | 171.54M | 193.98M | 152.61M | |
| Net current asset value | 83.73M | 54.71M | 106.24M | 145.33M | 105.53M | |
| Invested capital | 0.25 | 0.32 | 0.2 | 0.18 | 0.22 | |
| Average receivables | 35.03M | 46.19M | 21.29M | 15.86M | 17.84M | |
| Average payables | 4.76M | 4.33M | 3.78M | 3.55M | 4.87M | |
| Average inventory | 1.27M | 1.43M | 1.43M | 1.25M | 1.14M | |
| Days sales outstanding | 71.09 | 134.41 | 43.92 | 219.1 | 84.8 | |
| Days payables outstanding | 246.18 | 96.03 | 290.19 | 3.5K | -139.19 | |
| Days of inventory on hand | 72.91 | 35.99 | 110.34 | 1.13K | -26.38 | |
| Receivables turnover | 1.27 | 0.67 | 2.05 | 0.41 | 1.06 | |
| Payables turnover | 0.37 | 0.94 | 0.31 | 0.03 | -0.65 | |
| Inventory turnover | 1.23 | 2.5 | 0.82 | 0.08 | -3.41 | |
| ROE | 0.09 | -0.35 | 0.34 | 0.09 | -0.3 | |
| Capex per share | -0.01 | -0.01 | 0 | -0.01 | 0 |
MGNX Frequently Asked Questions
What is MacroGenics, Inc. stock symbol ?
MacroGenics, Inc. is a US stock , located in Rockville of Md and trading under the symbol MGNX
What is MacroGenics, Inc. stock quote today ?
MacroGenics, Inc. stock price is $15.71 today.
Is MacroGenics, Inc. stock public?
Yes, MacroGenics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.62M
- Market Capitalization 1.09B
- Employee 357
- CEO Dr. Scott Koenig M.D., Ph.D.
- Headquarters Rockville,MD,US
- IPO Date 2013-10-10
-
Website
https://www.macrogenics.com 
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
